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Introduction
An Alzheimer’s diagnosis is an
overwhelming and devastating
diagnosis for both patients and
families. Now imagine if this diagnosis
was made at age 55. Instead of
looking forward to retirement and
grandchildren, these people are
preparing for a debilitating disease that
will rob them of their memory, cognitive
and functional abilities. Early-onset
familial Alzheimer’s disease (EOFAD)
affects people before the age of 65.
Although extremely rare, some exhibit
symptoms as early as in their 30s.
One of the things most frustrating
about this disease is so little is known
about its cause. That and the fact
there is no cure. There is research
which demonstrates a connection
between three gene mutations and the
incidence of EOFAD. Knowledge of
the potential cause behind their
disease may help some patients and
families better understand and cope
with this disease.
EOFAD is rare. It is estimated only
five percent of all Alzheimer’s
diagnoses can be attributed to early
onset. In 2011, the Alzheimer’s
Association estimated 200,000
persons were afflicted with this disease
in the United States (Barber, 2012).
However, these numbers include both
familial and sporadic forms. It is likely
EOFAD accounts for less than one
percent of all cases of Alzheimer’s
disease (Orphanet, 2009).

Pathophysiological Processes

Implications for
Nursing Care

 Signs and Symptoms

In order to treat the cognition,
behavior and functional abilities of
EOFAD, both pharmacologic and
nonpharmacologic interventions are
needed. The top goals of treatment
are focused on maintaining quality of
life, ensuring a safe environment,
maximize function in daily activities.
Support and education for the patient
and family is imperative. Encourage
the preparation of a living will and/or
durable power of attorney for health
care (Alzheimer’s Association, 2014c).

EOFAD is a progressive dementia that affects cognition, behavior and functional
abilities. EOFAD progresses the same way as late-onset Alzheimer's disease
however it affects patients at an earlier age, has definite family history, various
non-cognitive neurological signs and symptoms, and is thought to have a more
aggressive course and shorter survival time (Panegyres, & Huei-Yang, 2013)
The seven stages of Alzheimer's disease:
Stage 1: No impairment. No symptoms of dementia, normal function
Stage 2: Very mild cognitive decline. No symptoms of dementia detected but
person may forget familiar words or location of everyday objects.
Stage 3: Mild cognitive decline. Memory or concentration problems may be
detected. Problems may include trouble planning or organizing, greater difficulties
performing tasks in social or work settings.
Stage 4: Moderate cognitive decline. Specific symptoms can be identified such as
forgetting recent events and/or own personal history, becoming moody or
withdrawn, increasing difficulty with complex tasks.
Stage 5: Moderately severe cognitive decline. Memory gaps are evident,
assistance is needed with day to day activities. Confusion may exist about where
they are or what day it is, trouble with mental arithmetic.
Stage 6: Severe cognitive decline. Extensive assistance is needed with daily
activities, memory worsens, personality changes may occur. trouble remembering
names of spouse or caregiver, changes in sleep patterns, frequent trouble with
bowel and bladder control, may wander and become lost.
Stage 7: Very severe cognitive decline. Ability to respond to environment is
lost. Need maximum assistance with personal care, reflexes abnormal, swallowing
impaired (Alzheimer’s Association, 2014a)

Gene mutation differences in EOFAD and late-onset Alzheimer's (Neuroa, 2014)

 Underlying Pathophysiology
EOFAD is an inherited autosomal dominant disease. Scientists have discovered 3
rare deterministic genes that have been identified as a cause the disease: amyloid
precursor protein (APP) on chromosome 21 accounts for 10-15% of EOFAD,
presenilin-1 (PS1) on chromosome 14 accounts for 75-80% of EOFAD, and
presenilin-2 (PS2) on chromosome 1 accounts for <5% of EOFAD (Wu et al., 2012).
Each of these mutations contributes to the breakdown of APP. The result of this
breakdown process is the formation of harmful beta-amyloid protein fragments that
are the main components of plaques (National Institute on Aging, 2014). The plaques
build up and interrupt communication between neurons. These amyloid plaques are
a hallmark of the disease, in addition to cerebral cortical atrophy and intraneuronal
neurofibrillary tangles (Bird, 2012). These intraneuronal tangles cause damage to
brain cells and synapses. The cerebral cortex and hippocampus shrinks and the
ventricles enlarge.

Alzheimer’s disease is a dreadful
and insidious disease to have
regardless of age but it is especially
hard when it affects individuals in the
prime of their life. This disease robs
people of their lives and leaves the
remnants for the families and loved
ones. Often times EOFAD is
misdiagnosed, not recognized and
inadequately managed. Dementia in
the young is overshadowed by the
aging population (Armari, Jarmolowicz
& Panegyres, 2013). Because EOFAD
is so exceptionally rare, it has not
received much attention. Unlike other
diseases, it lacks the visibility, funding
and advocacy groups. Additionally, it
has not been included in any clinical
studies or drug trials (Strobel, 2014).

Generic

Brand

Approved for

donepezil

Aricept

all stages

galantamine

Razadyne

mild to moderate

memantine

Namenda

moderate to severe

rivastigmine

Exelon

all stages

tacrine

Cognex

mild to moderate
FDA approved Alzheimer’s drugs

People who inherit an early onset Alzheimer's mutation have a nearly 100%
chance of developing the disease. Each child of a parent with an early-onset
mutation has a 50/50 chance of inheriting the disease. EOFAD is extremely rare, an
estimated 1% or less of Alzheimer's cases are attributed these genes (Orphanet,
2009).

 Significance of Pathophysiology

Cortical shrinkage (Neuroa, 2014)

There are five FDA approved drugs
that treat the symptoms of Alzheimer’s
disease (Alzheimer’s Association,
2014c):

Conclusion

Genetic testing and counseling can be offered to the rare families that have the
known genetic mutation for EOFAD. However, since there are currently no treatments
to prevent, cure or even slow the process of Alzheimer’s, this testing would have little
to no effect on medical treatment decisions (Alzheimer’s Association, 2014b). It
could, however, help families make decisions about financial matters, reproduction
and career planning (Bird, 2012). Although not common, if the disease causing
mutation has been identified in the family, prenatal testing can be done by DNA
analysis of the fetal cells.
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